Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a large format version of its Endoform® Natural product.
The largest of Aroa’s wound care products, the 8.5 by 6-inch device has been launched in the United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system.
Aroa Biosurgery Chief Executive, Brian Ward said this large-format version of Endoform® Natural addresses the growing need to treat large wounds with a single sheet of their extracellular matrix-based product and provides more options for clinicians.
“We saw a need to offer Healthcare Providers a simple option for larger and often more difficult-to-treat wounds arising from trauma and complications from surgical wounds, or other diseases where healing is impaired. This format is also suitable for wounds such as chronic wounds and venous leg ulcers.
“We are also seeing that Endoform® Natural is increasingly being used in conjunction with negative pressure wound therapy, and this large-format will be particularly useful in these treatment applications.”
Aroa Biosurgery intends to make the large format available in a range of global markets as and when regulatory approvals are granted.
“Aroa is committed to having solutions for a wide variety of wounds and wound sizes, and to partnering with clinicians to ensure there are effective solutions for patients presenting with an array of challenging wounds,” says Brian Ward.